查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1473817

黃體素市場規模 - 按配方（天然、合成）、給藥途徑（注射、口服）、應用（避孕、更年期）、藥物類型（學名藥、品牌）、類型（處方藥、非處方藥）、配銷通路和預測， 2024 年 - 2032

Progesterone Market Size - By Formulation (Natural, Synthetic), Route of Administration (Injectable, Oral), Application (Contraception, Menopause), Drug Type (Generic, Branded), Type (Prescription, OTC), Distribution Channel & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於人們對多囊性卵巢症候群 (PCOS)、不孕症和月經不規則等荷爾蒙相關疾病的認知和診斷不斷提高，黃體酮市場規模預計在 2024 年至 2032 年間複合年成長率為 12.7%。根據世界衛生組織的數據，到 2023 年，預計多囊性卵巢症候群會影響 8% 至 13% 的育齡女性，其中全球多達 70% 的受影響女性仍未被診斷出來。醫療保健提供者擴大開出黃體酮藥物來解決這些問題。人口老化和更年期症狀的增加進一步需要荷爾蒙替代療法。

此外，藥物配方和藥物傳輸技術的進步正在提高黃體酮產品的功效和安全性，促進其在臨床環境中的採用。緩釋製劑和經皮貼片等創新提供了便捷的給藥途徑並提高了患者的依從性。專注於探索黃體酮在癌症治療、神經病學和精神病學等領域的治療潛力的不斷擴大的研究活動也將推動市場成長。

黃體酮產業根據配方、給藥途徑、應用、藥物類型、類型、配銷通路和地區進行分類。

從應用來看，2024年至2032年，避孕領域的市場規模預計將實現13.1%的複合年成長率。推動的。旨在提高黃體酮避孕藥的安全性、有效性和便利性的持續研發工作也為產品製造商和利害關係人提供了利潤豐厚的機會。

根據類型，OTC 領域的黃體酮產業在 2024 年至 2032 年期間的複合年成長率將達到 12.4%。消費者對女性健康的認知和賦權不斷增強，加上獲得非處方藥產品的便利性，有利於這一成長。此外，無需處方即可獲得黃體酮乳膏、凝膠和補充劑，為管理荷爾蒙相關病症提供了更大的自主權，從而擴大了消費者基礎。

亞太地區黃體酮產業預計到2032 年將實現12.3% 的成長率，這歸因於人口的迅速成長，以及解決多囊性卵巢症候群和不孕症等荷爾蒙相關疾病的意識和獲得醫療保健服務的不斷提高。家庭規模縮小和生育延遲的文化轉變導致擴大採用含有黃體酮的荷爾蒙避孕藥。此外，印度和中國強大的藥品製造業將促進黃體酮藥物的本地生產，以確保供應鏈的彈性和可負擔性，並刺激區域產業的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 荷爾蒙失調的盛行率不斷增加
      • 人們對女性健康的認知不斷提高
      • 有利的政府措施和醫療保健政策
    • 產業陷阱與挑戰
      • 副作用和安全問題
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按配方分類，2018 年 - 2032 年

  • 主要趨勢
  • 自然的
  • 合成的

第 6 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

  • 主要趨勢
  • 可注射
  • 口服
  • 經皮
  • 其他給藥途徑

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 停經
  • 避孕
  • 功能性子宮出血
  • 增生性前驅病變
  • 子宮內膜癌
  • 其他應用

第 8 章：市場估計與預測：按藥物類型，2018 - 2032

  • 主要趨勢
  • 品牌化
  • 通用的

第 9 章：市場估計與預測：按類型，2018 - 2032

  • 處方
  • 場外交易

第 10 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第 11 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 12 章：公司簡介

  • Alkem Laboratories Ltd.
  • Aquatic Group
  • Bionpharma Inc.
  • Cadila Pharmaceuticals
  • Cipla Inc.
  • Estrellas Life Sciences Private Limited.
  • Eli Lily & Company
  • Glenmark Pharmaceuticals Ltd.
  • Insud Pharma S.L.U.
  • Lupin
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: 8310

Progesterone market size is estimated to witness 12.7% CAGR between 2024 and 2032, owing to increasing awareness and diagnosis of hormone-related disorders, such as polycystic ovary syndrome (PCOS), infertility, and menstrual irregularities. As per WHO, in 2023, PCOS affected an estimated 8 to 13% of reproductive-aged women, with up to 70% of the affected women remaining undiagnosed worldwide. Healthcare providers are increasingly prescribing progesterone medications to address these conditions. The aging population and rising instances of menopausal symptoms are further necessitating hormone replacement therapies.

Moreover, advancements in pharmaceutical formulations and drug delivery technologies are enhancing the efficacy and safety profile of progesterone products, fostering their adoption in clinical settings. Innovations, such as sustained-release formulations and transdermal patches offer convenient administration routes and improved patient compliance. The expanding research activities focused on exploring the therapeutic potential of progesterone in areas like cancer treatment, neurology, and psychiatry will also drive the market growth.

The progesterone industry is classified on the basis of formulation, route of administration, application, drug type, type, distribution channel, and region.

By application, the market size from the contraception segment is poised to witness 13.1% CAGR from 2024 to 2032. This is driven by the increasing global emphasis on family planning initiatives and the growing acceptance of hormonal contraceptives among women. The ongoing R&D efforts aimed at enhancing the safety, efficacy, and convenience of progesterone-based contraceptives are also offering lucrative opportunities for the product manufacturers and stakeholders.

Based on type, the progesterone industry from the OTC segment will record 12.4% CAGR during 2024-2032. The growth is favored by the increasing consumer awareness and empowerment regarding women's health, coupled with the convenience of access to OTC products. Furthermore, the availability of progesterone creams, gels, and supplements without the need for a prescription offers greater autonomy in managing hormone-related conditions, thereby expanding the consumer base.

Asia Pacific progesterone industry is slated to witness a 12.3% growth rate through 2032, attributed to the burgeoning population, coupled with increasing awareness and access to healthcare services to address hormone-related disorders, such as PCOS and infertility. The cultural shifts towards smaller family sizes and delayed childbearing are contributing to the rising adoption of hormonal contraceptives containing progesterone. Additionally, the presence of a robust pharmaceutical manufacturing sector in India and China will foster the local production of progesterone medications for ensuring supply chain resilience and affordability, stimulating the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data validation
  • 1.4 Forecast parameters
  • 1.5 Data sources
    • 1.5.1 Primary
    • 1.5.2 Secondary
      • 1.5.2.1 Paid sources
      • 1.5.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of hormonal disorders
      • 3.2.1.2 Rising awareness about women's health
      • 3.2.1.3 Favorable government initiatives and healthcare policies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Formulation, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Natural
  • 5.3 Synthetic

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Injectable
  • 6.3 Oral
  • 6.4 Transdermal
  • 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Menopause
  • 7.3 Contraception
  • 7.4 Dysfunctional uterine bleeding
  • 7.5 Hyperplastic precursor lesions
  • 7.6 Endometrial cancer
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Branded
  • 8.3 Generic

Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 9.1 Prescription
  • 9.2 OTC

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospital pharmacy
  • 10.3 Retail pharmacy
  • 10.4 Online pharmacy

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Alkem Laboratories Ltd.
  • 12.2 Aquatic Group
  • 12.3 Bionpharma Inc.
  • 12.4 Cadila Pharmaceuticals
  • 12.5 Cipla Inc.
  • 12.6 Estrellas Life Sciences Private Limited.
  • 12.7 Eli Lily & Company
  • 12.8 Glenmark Pharmaceuticals Ltd.
  • 12.9 Insud Pharma S.L.U.
  • 12.10 Lupin
  • 12.11 Novo Nordisk A/S
  • 12.12 Teva Pharmaceutical Industries Ltd